NASDAQ: ENSCW Ensysce Biosciences, Inc. 10-K

Ensysce launches Phase 3 trial for PF614, raises $4M, extends cash runway to Q2 2026

Filed March 30, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 10, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ENSCW commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.